FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1275-1284

  Zhou, Jun Dong ^a   Shen, Fei ^b   Ji, Jian Song ^c   Zheng, Kai ^a   Huang, Min ^a   Wu, Jin Chang ^a  

^a SUZHOU MUNICIPAL HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c LISHUI UNIVERSITY   (China)

Author keywords

Anti apoptosis; Cancer testis; FAM9C; Hepatocellular carcinoma; PI3K Akt; RNA interference

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FAM9C; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FAM9C GENE; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; KNOCKOUT GENE; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; MICE, NUDE; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880640691     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2592     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Kew MC: Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol 12: 173-182, 2013.
4. Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A: Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 39: 473-485, 2012.
5. Alsinet C and Villanueva A: Genomic prognostic markers in hepatocellular carcinoma. Gastroenterol Hepatol 35: 94-101, 2012 (In Spanish). 6. Sherman M: Modern approach to hepatocellular carcinoma. Curr Gastroenterol Rep 13: 49-55, 2011.
6. Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625, 2005.
7. Zhao L, Mou DC, Leng XS, et al: Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10: 2034-2038, 2004.
8. Peng JR, Chen HS, Mou DC, et al: Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219: 223-232, 2005.
9. Chen K, Huang W, Huang B, et al: BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma. Genet Test Mol Biomarkers 17: 160-165, 2013.
10. Xu H, Gu N, Liu ZB, et al: NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett 3: 39-44, 2012.
11. Martinez-Garay I, Jablonka S, Sutajova M, Steuernagel P, Gal A and Kutsche K: A new gene family (FAM9) of low-copy repeats in Xp22.3 expressed exclusively in testis: implications for recombinations in this region. Genomics 80: 259-267, 2002.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
13. Kang TH, Noh KH, Kim JH, et al: Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res 70: 3062-3070, 2010.
14. Guerrero-Preston R, Santella RM, Blanco A, Desai M, Berdasco M and Fraga M: Global DNA hypomethylation in liver cancer cases and controls: a phase I preclinical biomarker development study. Epigenetics 2: 223-226, 2007.
15. Akhavan-Niaki H and Samadani AA: DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys: Mar 19, 2013 (Epub ahead of print).
16. Niemeyer P, Tureci O, Eberle T, Graf N, Pfreundschuh M and Sahin U: Expression of serologically identified tumor antigens in acute leukemias. Leuk Res 27: 655-660, 2003.
17. Kalejs M, Ivanov A, Plakhins G, et al: Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer 6: 6, 2006.
18. Mobasheri MB, Jahanzad I, Mohagheghi MA, Aarabi M, Farzan S and Modarressi MH: Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev 31: 296-302, 2007.
19. Hosoya N, Okajima M, Kinomura A, et al: Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2. EMBO Rep 13: 44-51, 2012.
20. De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16 (Suppl 2): S17-S27, 2012.
21. Zhou Q, Wong CH, Lau CP, et al: Enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma. Int J Hepatol 2013: 103830, 2013.
22. Touil Y, Zuliani T, Wolowczuk I, et al: The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. Stem Cells 31: 641-651, 2012.
23. Almhanna K, Strosberg J and Malafa M: Targeting AKT protein kinase in gastric cancer. Anticancer Res 31: 4387-4392, 2011.
24. Gedaly R, Angulo P, Chen C, et al: The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res 32: 2531-2536, 2012.
25. Muntane J, De la Rosa AJ, Docobo F, Garcia-Carbonero R and Padillo FJ: Targeting tyrosine kinase receptors in hepatocellular carcinoma. Curr Cancer Drug Targets 13: 300-312, 2013.
26. Temirak A, Abdulla M and Elhefnawi M: Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma. Anticancer Agents Med Chem 12: 1088-1097, 2012.
27. Grabinski N, Ewald F, Hofmann BT, et al: Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11: 85, 2012.
28. Tao SF, Zhang CS, Guo XL, et al: Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells. World J Gastroenterol 18: 2334-2343, 2012.